Inventiva (NASDAQ:IVA) Sets New 12-Month Low - Here's What Happened

Key Points

• Inventiva shares hit a new 52-week low, falling to $3.10 before last trading at $3.12 on elevated volume of roughly 3.26 million shares.
• Despite the stock’s decline, analysts maintained a generally positive outlook: Inventiva has a consensus “Buy” rating and a $15.86 average price target, with Guggenheim and Truist raising their targets to $14 and $18, respectively.
• The company reported a quarterly loss of $0.14 per share and $0.75 million in revenue. Inventiva is developing lanifibranor, an investigational treatment for MASH currently being evaluated in a Phase 3 trial.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) reached a new 52-week low on Tuesday. The company traded as low as $3.10 and last traded at $3.12, with a volume of 3,264,826 shares traded. The stock had previously closed at $3.16.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IVA. Cantor Fitzgerald assumed coverage on Inventiva in a research report on Friday, July 17th. They issued an "overweight" rating for the company. Weiss Ratings lowered Inventiva from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday. Wall Street Zen raised Inventiva from a "sell" rating to a "hold" rating in a research note on Saturday, October 3rd. Guggenheim increased their price objective on Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Finally, Truist Financial raised their price objective on Inventiva from $13.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Inventiva has a consensus rating of "Buy" and a consensus price target of $15.86.

Inventiva Price Performance

The firm has a 50 day moving average of $4.18 and a two-hundred day moving average of $4.54.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $0.75 million during the quarter. As a group, analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inventiva

Hedge funds have recently bought and sold shares of the company. Eventide Asset Management LLC purchased a new position in Inventiva in the fourth quarter worth about $1,155,000. Seven Fleet Capital Management LP purchased a new stake in shares of Inventiva during the first quarter valued at approximately $1,111,000. Persistent Asset Partners Ltd bought a new stake in shares of Inventiva during the fourth quarter valued at approximately $603,000. Engineers Gate Manager LP increased its position in shares of Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after acquiring an additional 43,280 shares in the last quarter. Finally, Platt Investment Counsel LLC purchased a new position in Inventiva in the 3rd quarter worth approximately $45,000. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.